Skip to main content

Vaxart, Inc.

VXRT
Exchange
OTC
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0000072444

No open-market purchases or sales by Vaxart, Inc. insiders were filed in the last 90 days; 4 institutions reported holding it in 13F filings for Q2 2026, worth $39.0K in total; no superinvestor holds it.

Q3 2022 vs. Q2 2022

How the institutions holding Vaxart, Inc. changed between Q2 2022 and Q3 2022.

All holders in Q3 2022All holders in Q2 2022

13F holders of VXRT: Q2 2022 compared with Q3 2022
MeasureQ2 2022Q3 2022Change
Holders146143−3
Shares44.5M50.8M+6.31M (+14.2%)
Value$155.6M$110.7M−$44.9M (−28.9%)

New holders (14)

Institutions that held Vaxart, Inc. at the end of Q3 2022 but not at the end of Q2 2022.

Institutions new to VXRT in Q3 2022
InstitutionSharesValue% of portfolio
Balyasny Asset Management LLC53,275$116.0K0.00%
Walleye Capital LLC43,210$94.0K0.00%
Edmond de Rothschild Holding S.A.30,000$65.0K0.00%
Squarepoint Ops LLC27,279$59.0K0.00%
Walleye Trading LLC24,756$54.0K0.00%
Kestra Advisory Services, LLC21,336$47.0K0.00%
Atom Investors LP17,757$39.0K0.01%
Two Sigma Advisers, LP15,500$34.0K0.00%
Cambridge Investment Research Advisors, Inc.10,832$24.0K0.00%
Activest Wealth Management10,440$23.0K0.01%
Operose Advisors LLC3,500$8.00K0.01%
Wipfli Financial Advisors LLC,2,000$4.00K0.00%
Quadrant Capital Group LLC642$1.00K0.00%
Bogart Wealth, LLC500$1.00K0.00%

Sold out (17)

Institutions that held Vaxart, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.